M&A Deal Summary |
|
|---|---|
| Date | 2025-09-25 |
| Target | Respira |
| Sector | Life Science |
| Buyer(s) | Gossamer Bio |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Sidley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
| Employees | 144 |
| Revenue | 115M USD (2024) |
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Gossamer Bio was founded in 2015 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-02-23 |
Gossamer Bio - Clinical Stage Integrin Activator Program
San Diego, California, United States Gossamer Bio's Clinical Stage Integrin Activator Program GB1275 has the potential to reduce innate immune cell driven autoimmunity in multiple therapeutic areas and significantly improve patients’ lives. Gossamer Bio's Clinical Stage Integrin Activator Program is based in San Diego, California. |
Sell | - |
